Vital Therapies Announces First Subject Enrolled In VTI-210 And Provides Update On Enrollment In VTI-208
December 08, 2014 at 08:02 AM EST
Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting treatment of acute liver ...
